Trial Profile

A Phase I/II Study of Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Tafasitamab (Primary)
Indications B-cell lymphoma; CNS cancer; Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 Jan 2024 Planned End Date changed from 30 Apr 2023 to 30 Jun 2026.
11 Jan 2024 Planned primary completion date changed from 30 Apr 2023 to 30 Sep 2025.
12 Dec 2023 According to Trial design presented at the 65th American Society of Hematology Annual Meeting and Exposition., The study is currently enrolling at the University of California San Francisco, with plans to expand enrollment to other institutions within the United States.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com